Pulsetto, founded in 2021 and headquartered in Lithuania, is carving its niche in the Health and Wellness and Medical Devices sectors with its advanced technology aimed at combating modern-day stressors. The company stands out with its flagship offering, an innovative vagus nerve stimulation (VNS) device, complemented by a user-friendly app. The product promises significant reductions in stress levels, anxiety, and sleep disorders, boasting a 64% stress reduction rate.
Recently secured a €400.00K seed investment in February 2025, Pulsetto is well-positioned for growth as it harnesses cutting-edge science and technology to deliver non-invasive solutions for mental clarity and overall well-being. This investment underscores potential confidence in the startup's viability and reflects its commitment to transforming lives through accessible neurological health interventions.